H. Lynn Starr, MD

  • 6Articles
  • 52.4KReads
  • 2014–2023Active
  • 32Collaborators
  • 194Citations

About

H. Lynn Starr, MD, has published extensively on the treatment and management of schizophrenia, schizoaffective disorders, and major depressive disorder, with a focus on long-acting injectable antipsychotics and treatment-resistant depression. The author’s work also addresses the longitudinal safety of esketamine nasal spray, caregiver burden in depression with suicidal ideation, and individualized dosing strategies for adult attention-deficit/hyperactivity disorder. Starr’s research includes clinical trial design and real-world outcomes related to antipsychotic therapies. The author has frequently collaborated with Larry Alphs and others at Janssen Scientific Affairs, LLC.

Publications

JCP
Earlier Use of Paliperidone Palmitate in Patients With Schizophrenia
Original Research

Earlier Use of Paliperidone Palmitate in Patients With Schizophrenia

September 25, 2023

Long-acting injectable antipsychotics (LAIs) are typically reserved for patients with a long history of schizophrenia. This analysis of 3 studies found benefit in initiating the LAI paliperidone palmitate earlier...
, , , et al
JCP
Esketamine Nasal Spray and Adverse Events Over Time
Original Research

Esketamine Nasal Spray and Adverse Events Over Time

September 19, 2022

This study looked at the occurrence and severity of adverse events over time with esketamine nasal spray in MDD patients also receiving an oral antidepressant.
, , , et al
PCC
Original Research

Cost Burden of Depression and Suicide on Caregivers

August 12, 2021

Do caregivers of patients with major depressive disorder (MDD) and suicidal ideation and/or suicide attempts have significantly greater direct and indirect costs compared to MDD-alone and non-MDD caregivers? Read...
, , , et al
JCP
Original Research

Methylphenidate Dosage for ADD/ADHD

January 25, 2017

Read a placebo-controlled study discussing OROS methylphenidate dosages in treatment for Adult Attention-Deficit/Hyperactivity Disorder (ADHD).
, , , et al
JCP
Original Research

Antipsychotic Therapy in Schizophrenia

April 14, 2015

Read a study discussing Real-World Outcomes of Paliperidone Palmitate compared to Daily Oral Antipsychotic Therapy in Schizophrenia.
, , , et al
JCP
Original Research

Design and Rationale of the Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE) Study: A Novel Comparative Trial of Once-Monthly Paliperidone Palmitate Versus Daily Oral Antipsychotic Treatment for Delaying Time to Treatment #01#

October 28, 2014

, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe